Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

BACKGROUND: Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’s mutanome, autologous tumor may be the best source of tumor-associated antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dillman, Robert O., Cornforth, Andrew N., Nistor, Gabriel I., McClay, Edward F., Amatruda, Thomas T., Depriest, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840808/
https://www.ncbi.nlm.nih.gov/pubmed/29510745
http://dx.doi.org/10.1186/s40425-018-0330-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840808/
https://www.ncbi.nlm.nih.gov/pubmed/29510745
http://dx.doi.org/10.1186/s40425-018-0330-1

Ejemplares similares